RNA-mediated immunotherapy regulating tumor immune microenvironment: next wave of cancer therapeutics.
| dc.contributor.author | Pandey, Poonam R | |
| dc.contributor.author | Young, Ken H | |
| dc.contributor.author | Kumar, Dhiraj | |
| dc.contributor.author | Jain, Neeraj | |
| dc.date.accessioned | 2022-03-01T17:49:43Z | |
| dc.date.available | 2022-03-01T17:49:43Z | |
| dc.date.issued | 2022-02-21 | |
| dc.date.updated | 2022-03-01T17:49:42Z | |
| dc.description.abstract | Accumulating research suggests that the tumor immune microenvironment (TIME) plays an essential role in regulation of tumor growth and metastasis. The cellular and molecular nature of the TIME influences cancer progression and metastasis by altering the ratio of immune- suppressive versus cytotoxic responses in the vicinity of the tumor. Targeting or activating the TIME components show a promising therapeutic avenue to combat cancer. The success of immunotherapy is both astounding and unsatisfactory in the clinic. Advancements in RNA-based technology have improved understanding of the complexity and diversity of the TIME and its effects on therapy. TIME-related RNA or RNA regulators could be promising targets for anticancer immunotherapy. In this review, we discuss the available RNA-based cancer immunotherapies targeting the TIME. More importantly, we summarize the potential of various RNA-based therapeutics clinically available for cancer treatment. RNA-dependent targeting of the TIME, as monotherapy or combined with other evolving therapeutics, might be beneficial for cancer patients' treatment in the near future. | |
| dc.identifier | 10.1186/s12943-022-01528-6 | |
| dc.identifier.issn | 1476-4598 | |
| dc.identifier.issn | 1476-4598 | |
| dc.identifier.uri | ||
| dc.language | eng | |
| dc.publisher | Springer Science and Business Media LLC | |
| dc.relation.ispartof | Molecular cancer | |
| dc.relation.isversionof | 10.1186/s12943-022-01528-6 | |
| dc.subject | Antibody | |
| dc.subject | Cancer | |
| dc.subject | Cytokine | |
| dc.subject | Dendritic cells | |
| dc.subject | Immunotherapy | |
| dc.subject | Nanoparticle | |
| dc.subject | RNA | |
| dc.subject | RNA therapy | |
| dc.subject | T cells | |
| dc.subject | Tumor immune microenvironment | |
| dc.title | RNA-mediated immunotherapy regulating tumor immune microenvironment: next wave of cancer therapeutics. | |
| dc.type | Journal article | |
| duke.contributor.orcid | Young, Ken H|0000-0002-5755-8932 | |
| pubs.begin-page | 58 | |
| pubs.issue | 1 | |
| pubs.organisational-group | Duke | |
| pubs.organisational-group | School of Medicine | |
| pubs.organisational-group | Clinical Science Departments | |
| pubs.organisational-group | Institutes and Centers | |
| pubs.organisational-group | Pathology | |
| pubs.organisational-group | Duke Cancer Institute | |
| pubs.publication-status | Published | |
| pubs.volume | 21 |
Files
Original bundle
- Name:
- 205, RNA Review, Neeraj, 2022 Mol Cancer.pdf
- Size:
- 1.9 MB
- Format:
- Adobe Portable Document Format